{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
CNS Pharmaceuticals, Inc.
Is CNS Pharmaceuticals, Inc. technically bullish or bearish?
As of May 1, 2025, CNS Pharmaceuticals, Inc. shows a mildly bearish trend, influenced by daily moving averages indicating bearish momentum, while weekly MACD and RSI suggest mild bullish signals, but overall sentiment remains pressured by bearish Bollinger Bands and Dow Theory.
What does CNS Pharmaceuticals, Inc. do?
CNS Pharmaceuticals, Inc. is a preclinical stage pharmaceutical company focused on developing anticancer drug candidates, particularly Berubicin for glioblastoma. It has a market cap of USD 4.53 million and reported a net profit loss of USD 4 million as of March 2025.
How big is CNS Pharmaceuticals, Inc.?
As of Jun 18, CNS Pharmaceuticals, Inc. has a market capitalization of 4.53 million, with net sales of 0.00 million and a net profit of -15.62 million over the last four quarters. The company reported shareholder's funds of 6.18 million and total assets of 8.70 million as of Dec 24.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
